• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

At­las-backed Kymera grabs $102M as its pro­tein degra­da­tion tech­nol­o­gy heads in­to clin­ic

6 years ago
R&D

Vir’s George Scan­gos teams up with his for­mer col­leagues at Bio­gen to press fast-for­ward on an­ti­body pro­grams for ...

6 years ago
People
R&D

Flag­ship merges two star­tups to build a $220M Reper­toire of T cell tech, ther­a­pies

6 years ago
Deals

Af­ter a year of big ad­vances, As­traZeneca CEO Pas­cal So­ri­ot takes home a ma­jor-league pay pack­age

6 years ago
People
Deals

Stan­ford stem cell pi­o­neer nets $194M from Gilead-Forty Sev­en buy­out

6 years ago
People
Deals

A biotech tests Wall Street's roiled wa­ters and comes away with a $75M IPO haul

6 years ago
R&D

Dis­ap­point­ing PhI­II re­sults dash As­traZeneca's hopes of re­viv­ing a tar­nished can­cer drug through Lyn­parza com­bo

6 years ago
R&D

As the coro­n­avirus pan­dem­ic con­tin­ues to rat­tle the world, bio­phar­ma braces for a few new shocks to the sys­tem

6 years ago
Coronavirus

Har­bour Bio­Med nets $75M in Se­ries B+ as first glob­al tri­al gets un­der­way

6 years ago
Financing

Back to the draw­ing board for triple-neg­a­tive breast can­cer tar­gets, re­searchers pro­pose new com­bo ap­proach

6 years ago
Discovery

Bris­tol My­ers scores new FDA nod for Op­di­vo/Yer­voy com­bo; US Army wants Gilead­'s po­ten­tial Covid-19 drug for in­fect­ed ...

6 years ago
News Briefing

A JP Mor­gan promise, a last-minute bid and the coro­n­avirus stock mar­ket — how Gilead’s Daniel O’Day nabbed ...

6 years ago
Deals
R&D

Is HKEX ready to re­turn to biotech busi­ness? In­no­Care tests wa­ters with hopes to fetch $257M in IPO

6 years ago
Financing
China

With WuXi and Al­ny­lam in tow, Vir en­lists NIH as it tests var­i­ous tools to fight the coro­n­avirus scourge

6 years ago
R&D
Coronavirus

An­a­lysts start to sort out which bio­phar­ma com­pa­nies’ R&D plans are most threat­ened by a pan­dem­ic

6 years ago
R&D
Coronavirus

In search of a Ku­ur: Cell Med­ica re­brands and re­groups, tak­ing a new name, a new CEO and new mon­ey

6 years ago
R&D

FDA drafts guid­ance on al­ter­nate elec­tron­ic for­mats, an­nounces sup­port for new da­ta stan­dards

6 years ago
FDA+

The glob­al top 50 bio­phar­ma com­pa­nies — End­points News style

6 years ago
R&D

Sil­ver­back Ther­a­peu­tics gets $78M boost to 'recon­cep­tu­al­ize' an­ti­body-drug con­ju­gates

6 years ago
Financing
Startups

Af­ter hit­ting big in mul­ti­ple myelo­ma, J&J, Gen­mab now have a new 'break­through' in NSCLC to boast about

6 years ago
FDA+

Intar­ci­a's speed bump at the FDA turns in­to a road­block, as reg­u­la­tors once again turn thumbs down on di­a­betes ...

6 years ago
R&D
Pharma

Bio­gen out­break now tied to 70 cas­es of coro­n­avirus as state to­tal more than dou­bles in 1 day

6 years ago
Coronavirus

Coro­n­avirus up­date: Eli Lil­ly staffer tests pos­i­tive, FDA post­pones in­spec­tions and AACR is can­celed as out­break ...

6 years ago
Coronavirus

Sy­neos up for sale — re­port; Takeda's Nin­laro fails PhI­II in mul­ti­ple myelo­ma; EMA braces for drug short­age

6 years ago
News Briefing
First page Previous page 845846847848849850851 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.